Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Indel Therapeutics has received third US patent covering the application of indel-based targeting for antimicrobial drug discovery.
Subscribe to our email newsletter
The core technology is based on a novel antimicrobial targeting paradigm.
The platform identifies and targets discrete amino acid insertion or deletion differences between essential homologous proteins that are evolutionarily conserved across the pathogen (bacteria) and humans.
The company can selectively target the pathogen protein, based upon these structural differences.
The proteins are targeted with small molecules without binding to the human counterpart, thereby potentially reducing toxicity and microbial resistance.
Indel CEO Malcolm Kendall said the claims in this patent – The Diagnosis and Treatment of Infectious Diseases through Indel-differentiated Proteins – further strengthen and consolidate the company’s intellectual property.